Anzeige
Mehr »
Login
Sonntag, 29.12.2024 Börsentäglich über 12.000 News von 681 internationalen Medien
Macht Trump Krypto wieder groß? Wie Trumps Aussagen die Krypto-Landschaft verändern könnten!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
592 Leser
Artikel bewerten:
(2)

The Private Equity Fund of Gilde Healthcare Acquires German Medtech Company Acti-Med

Finanznachrichten News

• Investment to support the global expansion of leading manufacturer of precision medical components and devices

UTRECHT, The Netherlands and FREIENSTEINAU, Germany, April 27, 2021 (GLOBE NEWSWIRE) -- The Private Equity fund of Gilde Healthcare, a specialist healthcare investor, has acquired Acti-Med, a leading international developer and manufacturer of high-quality medical components and devices for the medical and pharmaceutical industries.

Founded in 1997, Germany-based Acti-Med focuses on tailor-made, highly-regulated, cannulas and cannula systems for pharmaceutical and medical applications, jointly developed with international Original Equipment Manufacturers (OEMs). Headquartered in Freiensteinau (Germany) and with operations in Kozerkí (Poland), Acti-Med has attracted clients from all around the world by combining the highest development and engineering capabilities, offering superior quality and operational flexibility. Recent expansions into promising adjacent end markets, supported by innovative best-in-class products highlight the company's ambitions for growth.

Gilde Healthcare will collaborate with Acti-Med to further strengthen and expand its product portfolio in both the Ready for Market and Ready for Clean room segments, as well as further expand its manufacturing and design capacity to serve its increasing demands from its Pharma and Medical Device customers.

Andreas Schwalb, Founder and CEO of Acti-Med added: "Acti-Med has had a truly exciting journey over the last 24 years and I am proud to look back on how we have grown our company from scratch into a global leader in our field. I would like to thank everyone at Acti-Med for their invaluable contributions. Now is the right time in our development to bring significant new investment and competencies to support our growth. We are pleased to have attracted Gilde Healthcare, who bring deep sector knowledge and a constructive, collaborative mindset. I look forward to working with Gilde Healthcare for Acti-Med's successful future."

Rafael Natanek, Partner at Gilde Healthcare, added: "We are pleased to complete this acquisition of Acti-Med, a highly regarded contract manufacturer of tailor-made cannula and cannula systems with promising growth opportunities. The company has, through its design-skills, high-quality manufacturing, and ability to adapt been able to achieve rapid growth with current and new customers. We are excited to be investing in the companies continued growth and look forward supporting the management as we consider additional options, such as strategic acquisitions."

The shareholders of Acti-Med have been advised by DZ BANK Corporate Finance as exclusive M&A advisor.

Media contacts:

LifeSci Advisors
Frank Schwarz - fschwarz@lifesciadvisors.com / +49 17 26 15 31 60

Gilde Healthcare
Rafael Natanek - natanek@gildehealthcare.com / +31 61 18 44 63 0

About Acti-Med

Acti-Med is one of the leading manufacturers in the field of medical technology. Headquartered in Freiensteinau, Germany Acti-Med's competence lies in the development and production of cannulas and cannula systems. Acti-Med develops, produces and sells high-quality medical components and devices for medical and pharmaceutical industries. Our customers are located throughout a wide range of industries, including oncology, pain therapy, the pharmaceutical industry and veterinary medicine. For more information, visit the company's website at www.acti-med.de.

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion across two fund strategies: Private Equityand Venture & Growth. The Private Equity fund of Gilde Healthcare participates in profitable European lower mid-market healthcare companies with a prime focus on the Benelux and DACH region. The Private Equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. The Venture & Growth of Gilde Healthcare invests in medtech, healthtech and therapeutics in Europe and North America.
For more information, visit the company's website at www.gildehealthcare.com.


© 2021 GlobeNewswire (Europe)
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.